Key RSV Vaccines

Author(s):

Adam James, PharmD

A panelist discusses how physicians can navigate respiratory syncytial virus (RSV) vaccine selection by considering patient age, pregnancy status, and seasonality, highlighting the approved indications for Arexvy and Abrysvo, including maternal immunization to protect infants through passive immunity.

EP: 1.The Impact of Respiratory Syncytial Virus (RSV) on Vulnerable Populations

EP: 2.Identifying Candidates for RSV Vaccination

Now Viewing

EP: 3.Key RSV Vaccines

EP: 4.The Role of Community Pharmacists in RSV Vaccine Uptake

Summary for Physicians: Key RSV Vaccines and Indications

Currently available RSV vaccines include Arexvy (GSK) and Abrysvo (Pfizer, Inc). Both are approved for adults aged 60 years and older, but Abrysvo is also indicated for pregnant individuals (32 to 36 weeks gestation) to protect infants via passive immunity. Selection depends on patient age, pregnancy status, and timing relative to the RSV season.